Abiraterone (BioDeep_00000398823)
natural product
代谢物信息卡片
Abiraterone (CB-7598)
化学式: C24H31NO (349.2405516)
中文名称: 阿比特龙
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1[C@@H](CC2[C@](C1)([C@]3([C@@](CC=2)([C@]4([C@](CC3)(C(=CC4)C5=CN=CC=C5)C)[H])[H])[H])C)O
InChI: InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1
描述信息
A 3beta-sterol that is androsta-5,16-dien-3beta-ol substituted at position 17 by a 3-pyridyl group. Administered as the O-acetate, it is used for treatment of metastatic castrate-resistant prostate cancer.
L - Antineoplastic and immunomodulating agents > L02 - Endocrine therapy > L02B - Hormone antagonists and related agents
C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C242 - Anti-Androgen
C471 - Enzyme Inhibitor > C147923 - CYP17A1 Inhibitor
同义名列表
2 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:68642
- PubChem: 132971
- DrugBank: DB05812
- ChEMBL: CHEMBL254328
- CAS: 154229-19-3
- MoNA: CCMSLIB00000078019
- MetaboLights: MTBLC68642
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Lili Yu, Hong Sun, Minxia Che, Wentao Gai. Observation of Serological Index and Efficacy of Abiraterone Hydrochloride Tablets Combined with Endocrine Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
Archivos espanoles de urologia.
2023 Oct; 76(8):588-595. doi:
10.56434/j.arch.esp.urol.20237608.73. [PMID: 37960958] - Yigeng Feng, Hongwen Cao, Zixi Song, Lei Chen, Dan Wang, Renjie Gao. Qi Ling decoction enhances abiraterone treatment via suppression of autophagy in castration resistant prostate cancer.
Aging.
2022 12; 14(24):9942-9950. doi:
10.18632/aging.204427. [PMID: 36541904] - Yixin Hu, Jianyuan Wu, Xin Jiang, Guiying Chen, Yang Zhang, Luqin Si, Hongliang Jiang, Jiangeng Huang, Jianying Huang. Simultaneous determination of abiraterone and its five metabolites in human plasma by LC-MS/MS: Application to pharmacokinetic study in healthy Chinese subjects.
Journal of pharmaceutical and biomedical analysis.
2022 Aug; 217(?):114826. doi:
10.1016/j.jpba.2022.114826. [PMID: 35576735] - Zejie Mei, Tao Yang, Ying Liu, Yuanyuan Gao, Zemin Hou, Qian Zhuang, Dongyin He, Xuebin Zhang, Qilong Tan, Xuyou Zhu, Yingyi Qin, Xi Chen, Chengdang Xu, Cuidong Bian, Xinan Wang, Chenyang Wang, Denglong Wu, Shengsong Huang, Zhenfei Li. Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment.
Cell reports. Medicine.
2022 05; 3(5):100608. doi:
10.1016/j.xcrm.2022.100608. [PMID: 35584629] - J Matthijs Moll, Johannes Hofland, Wilma J Teubel, Corina M A de Ridder, Angela E Taylor, Ralph Graeser, Wiebke Arlt, Guido W Jenster, Wytske M van Weerden. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
The Prostate.
2022 04; 82(5):505-516. doi:
10.1002/pros.24297. [PMID: 35037287] - Yu-Chao Ni, Jin-Ge Zhao, Meng-Ni Zhang, Yi-Jun Zhang, Zhen-Yu Yang, Ni Chen, Jun-Ru Chen, Peng-Fei Shen, Guang-Xi Sun, Xing-Ming Zhang, Yong-Hong Li, Hao Zeng. Predictors of efficacy of corticosteroid switching from abiraterone plus prednisone to dexamethasone in patients with metastatic castration-resistant prostate cancer.
Asian journal of andrology.
2022 Mar; 24(2):154-160. doi:
10.4103/aja202143. [PMID: 34380864] - Michalis Liontos, Evangelos Terpos, Elena Kunadis, Flora Zagouri, Alexandros Briasoulis, Efi Skafida, Oraianthi Fiste, Christos Markellos, Angeliki Andrikopoulou, Sentiljana Gumeni, Maria Kaparelou, Konstantinos Koutsoukos, Maria Gavriatopoulou, Efstathios Kastritis, Ioannis P Trougakos, Meletios- Athanasios Dimopoulos. Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients.
Prostate cancer and prostatic diseases.
2022 03; 25(1):117-118. doi:
10.1038/s41391-021-00455-9. [PMID: 34628475] - Lucie-Marie Scailteux, Fabien Despas, Frédéric Balusson, Boris Campillo-Gimenez, Romain Mathieu, Sébastien Vincendeau, André Happe, Emmanuel Nowak, Sandrine Kerbrat, Emmanuel Oger. Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: A French population-based study on prostate cancer patients.
British journal of clinical pharmacology.
2022 01; 88(1):336-346. doi:
10.1111/bcp.14972. [PMID: 34224605] - Yoshiyuki Sakai, Tatsuki Fukami, Mai Nagaoka, Keiya Hirosawa, Hiroyuki Ichida, Rei Sato, Kohei Suzuki, Masataka Nakano, Miki Nakajima. Arylacetamide deacetylase as a determinant of the hydrolysis and activation of abiraterone acetate in mice and humans.
Life sciences.
2021 Nov; 284(?):119896. doi:
10.1016/j.lfs.2021.119896. [PMID: 34450168] - Elahe A Mostaghel, Brett T Marck, Orpheus Kolokythas, Felix Chew, Evan Y Yu, Michael T Schweizer, Heather H Cheng, Phillip W Kantoff, Steven P Balk, Mary-Ellen Taplin, Nima Sharifi, Alvin M Matsumoto, Peter S Nelson, R Bruce Montgomery. Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2021 11; 27(21):6001-6011. doi:
10.1158/1078-0432.ccr-21-1819. [PMID: 34407973] - Hui-Ming Lin, Blossom Mak, Nicole Yeung, Kevin Huynh, Thomas G Meikle, Natalie A Mellett, Edmond M Kwan, Heidi Fettke, Ben Tran, Ian D Davis, Kate L Mahon, Alison Zhang, Martin R Stockler, Karen Briscoe, Gavin Marx, Megan Crumbaker, Phillip D Stricker, Pan Du, Jianjun Yu, Shidong Jia, Tahlia Scheinberg, Michael Fitzpatrick, Paul Bonnitcha, David R Sullivan, Anthony M Joshua, Arun A Azad, Lisa M Butler, Peter J Meikle, Lisa G Horvath. Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase.
EBioMedicine.
2021 Oct; 72(?):103625. doi:
10.1016/j.ebiom.2021.103625. [PMID: 34656931] - Jian Pan, Jun Wang, Yu Wei, Tingwei Zhang, Sheng Zhang, Dingwei Ye, Yao Zhu. Combination of body mass index and albumin predicts the survival in metastatic castration-resistant prostate cancer patients treated with abiraterone: A post hoc analysis of two randomized trials.
Cancer medicine.
2021 10; 10(19):6697-6704. doi:
10.1002/cam4.4205. [PMID: 34414685] - Hiromi Kanji, Shizuyo Horiyama, Tetsutaro Kimachi, Jun Haginaka. Determination of Abiraterone and Its Metabolites in Human Serum by LC-ESI-TOF/MS Using Solid-phase Extraction.
Analytical sciences : the international journal of the Japan Society for Analytical Chemistry.
2021 Sep; 37(9):1281-1287. doi:
10.2116/analsci.21p035. [PMID: 33678729] - Sha Zhu, Yuchao Ni, Guangxi Sun, Zilin Wang, Junru Chen, Xingming Zhang, Jinge Zhao, Xudong Zhu, Jindong Dai, Zhenhua Liu, Jiayu Liang, Haoran Zhang, Yaowen Zhang, Pengfei Shen, Hao Zeng. Exosomal TUBB3 mRNA expression of metastatic castration-resistant prostate cancer patients: Association with patient outcome under abiraterone.
Cancer medicine.
2021 09; 10(18):6282-6290. doi:
10.1002/cam4.4168. [PMID: 34318630] - Matti Annala, Sinja Taavitsainen, Daniel J Khalaf, Gillian Vandekerkhove, Kevin Beja, Joonatan Sipola, Evan W Warner, Cameron Herberts, Amanda Wong, Simon Fu, Daygen L Finch, Conrad D Oja, Joanna Vergidis, Muhammad Zulfiqar, Bernhard J Eigl, Christian K Kollmansberger, Matti Nykter, Martin E Gleave, Kim N Chi, Alexander W Wyatt. Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2021 08; 27(16):4610-4623. doi:
10.1158/1078-0432.ccr-21-1625. [PMID: 34083234] - M Del Re, V Conteduca, S Crucitta, G Gurioli, C Casadei, G Restante, G Schepisi, C Lolli, F Cucchiara, R Danesi, U De Giorgi. Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide.
Prostate cancer and prostatic diseases.
2021 06; 24(2):524-531. doi:
10.1038/s41391-020-00309-w. [PMID: 33500577] - T Szarvas, A Csizmarik, M Váradi, T Fazekas, A Hüttl, P Nyirády, B Hadaschik, V Grünwald, S Tschirdewahn, S F Shariat, S Sevcenco, A Maj-Hes, G Kramer. The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy.
Urologic oncology.
2021 05; 39(5):296.e11-296.e19. doi:
10.1016/j.urolonc.2020.09.005. [PMID: 33046366] - Azariyas A Challa, Adam Christopher Calaway, Jennifer Cullen, Jorge Garcia, Nihar Desai, Neal L Weintraub, Anita Deswal, Shelby Kutty, Ajay Vallakati, Daniel Addison, Ragavendra Baliga, Courtney M Campbell, Avirup Guha. Cardiovascular Toxicities of Androgen Deprivation Therapy.
Current treatment options in oncology.
2021 04; 22(6):47. doi:
10.1007/s11864-021-00846-z. [PMID: 33866442] - Mamta Parikh, Chengfei Liu, Chun-Yi Wu, Christopher P Evans, Marc Dall'Era, Daniel Robles, Primo N Lara, Neeraj Agarwal, Allen C Gao, Chong-Xian Pan. Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer.
Scientific reports.
2021 03; 11(1):6377. doi:
10.1038/s41598-021-85969-x. [PMID: 33737681] - Ali Ghoochani, En-Chi Hsu, Merve Aslan, Meghan A Rice, Holly M Nguyen, James D Brooks, Eva Corey, Ramasamy Paulmurugan, Tanya Stoyanova. Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer.
Cancer research.
2021 03; 81(6):1583-1594. doi:
10.1158/0008-5472.can-20-3477. [PMID: 33483372] - Thaís Luise Dillenburg Weiss, Gustavo Gössling, Marina Venzon Antunes, Gilberto Schwartsmann, Rafael Linden, Simone Gasparin Verza. Evaluation of dried blood spots as an alternative matrix for therapeutic drug monitoring of abiraterone and delta(4)-abiraterone in prostate cancer patients.
Journal of pharmaceutical and biomedical analysis.
2021 Feb; 195(?):113861. doi:
10.1016/j.jpba.2020.113861. [PMID: 33373824] - Abhinav Khanna, Luke P O'Connor, Prithvi B Murthy, Darren J Bryk, Michele Fascelli, Kyle Ericson, Nitin K Yerram, Samuel C Haywood, Robert Abouassaly. Contemporary management of advanced prostate cancer: an evolving landscape.
Clinical advances in hematology & oncology : H&O.
2021 Feb; 19(2):108-118. doi:
NULL. [PMID: 33596192] - Tibor Szarvas, Anita Csizmarik, Tamás Fazekas, András Hüttl, Péter Nyirády, Boris Hadaschik, Viktor Grünwald, Lukas Püllen, Zsolt Jurányi, Zsuzsa Kocsis, Shahrokh F Shariat, Sabina Sevcenco, Agnieszka Maj-Hes, Gero Kramer. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
BJU international.
2021 01; 127(1):44-55. doi:
10.1111/bju.15086. [PMID: 32314509] - Cameron M Armstrong, Chengfei Liu, Liangren Liu, Joy C Yang, Wei Lou, Ruining Zhao, Shu Ning, Alan P Lombard, Jinge Zhao, Leandro S D'Abronzo, Christopher P Evans, Pui-Kai Li, Allen C Gao. Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2020 11; 26(22):6064-6074. doi:
10.1158/1078-0432.ccr-20-1682. [PMID: 32928794] - Thaís Luise Dillenburg Weiss, Carolina Mesquita Furtado, Marina Venzon Antunes, Gustavo Gössling, Gilberto Schwartsmann, Rafael Linden, Simone Gasparin Verza. A quick UPLC-MS/MS method for therapeutic drug monitoring of abiraterone and delta(4)-abiraterone in human plasma.
Biomedical chromatography : BMC.
2020 Nov; 34(11):e4947. doi:
10.1002/bmc.4947. [PMID: 32652651] - Shiori Nakajima, Takamitsu Inoue, Mingguo Huang, Koichiro Takayama, Soki Kashima, Ryohei Yamamoto, Atsushi Koizumi, Taketoshi Nara, Kazuyuki Numakura, Mitsuru Saito, Shintaro Narita, Masatomo Miura, Shigeru Satoh, Tomonori Habuchi. Does the Addition of Abiraterone to Castration Affect the Reduction in Bone Mineral Density?.
In vivo (Athens, Greece).
2020 Nov; 34(6):3291-3299. doi:
10.21873/invivo.12167. [PMID: 33144436] - Atul Bhatnagar, Matthew J McKay, Malmaruha Arasaratnam, Megan Crumbaker, Howard Gurney, Mark P Molloy. Evaluating bioanalytical capabilities of paper spray ionization for abiraterone drug quantification in patient plasma.
Journal of mass spectrometry : JMS.
2020 Oct; 55(10):e4584. doi:
10.1002/jms.4584. [PMID: 32725840] - Shuofeng Yuan, Jasper F W Chan, Kenn K H Chik, Chris C Y Chan, Jessica O L Tsang, Ronghui Liang, Jianli Cao, Kaiming Tang, Lin-Lei Chen, Kun Wen, Jian-Piao Cai, Zi-Wei Ye, Gang Lu, Hin Chu, Dong-Yan Jin, Kwok-Yung Yuen. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.
Pharmacological research.
2020 09; 159(?):104960. doi:
10.1016/j.phrs.2020.104960. [PMID: 32473310] - Vincenza Conteduca, Daniel Wetterskog, Emanuela Scarpi, Alessandro Romanel, Giorgia Gurioli, Anuradha Jayaram, Cristian Lolli, Delila Gasi Tandefelt, Giuseppe Schepisi, Chiara Casadei, Anna Wingate, Federica Matteucci, Giovanni Paganelli, Enrique Gonzalez-Billalabeitia, Francesca Demichelis, Ugo De Giorgi, Gerhardt Attard. Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer.
British journal of cancer.
2020 09; 123(6):982-987. doi:
10.1038/s41416-020-0969-5. [PMID: 32669676] - Eleanor Jing Yi Cheong, Pramod C Nair, Rebecca Wan Yi Neo, Ho Thanh Tu, Fu Lin, Edmund Chiong, Kesavan Esuvaranathan, Hao Fan, Russell Z Szmulewitz, Cody J Peer, William D Figg, Christina Li Lin Chai, John O Miners, Eric Chun Yong Chan. Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen.
The Journal of pharmacology and experimental therapeutics.
2020 09; 374(3):438-451. doi:
10.1124/jpet.120.265868. [PMID: 32554434] - Nima Sharifi. Homozygous HSD3B1(1245C) inheritance and poor outcomes in metastatic castration-resistant prostate cancer with abiraterone or enzalutamide: what does it mean?.
Annals of oncology : official journal of the European Society for Medical Oncology.
2020 09; 31(9):1103-1105. doi:
10.1016/j.annonc.2020.06.009. [PMID: 32592760] - Lucil Carril-Ajuria, Yuly A Remolina-Bonilla, Alberto Carretero-Gonzalez, Maricruz Martin-Soberon, Daniel Castellano, Christianne Bourlon, Guillermo de Velasco, Maria T Bourlon. Challenges of Treating a Patient With Advanced Prostate Cancer During the COVID-19 Pandemic.
Oncology (Williston Park, N.Y.).
2020 08; 34(8):317-319. doi:
10.46883/onc.2020.3408.0317. [PMID: 32785928] - M van Nuland, S L Groenland, A M Bergman, N Steeghs, H Rosing, N Venekamp, A D R Huitema, J H Beijnen. Exposure-response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer.
Prostate cancer and prostatic diseases.
2020 06; 23(2):244-251. doi:
10.1038/s41391-019-0179-5. [PMID: 31611636] - Chang Liu, Yao Zhu, Hengchuan Su, Xiaoping Xu, Yingjian Zhang, Shaoli Song, Beihe Wang, Dingwei Ye, Silong Hu. Preliminary results of targeted prostate-specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castration-resistant prostate cancer.
Cancer medicine.
2020 05; 9(10):3278-3286. doi:
10.1002/cam4.2964. [PMID: 32163676] - Connor Wright, Patrick O'Day, Mohammed Alyamani, Nima Sharifi, Richard J Auchus. Abiraterone acetate treatment lowers 11-oxygenated androgens.
European journal of endocrinology.
2020 Apr; 182(4):413-421. doi:
10.1530/eje-19-0905. [PMID: 32045360] - Joanie Vaillancourt, Véronique Turcotte, Patrick Caron, Lyne Villeneuve, Louis Lacombe, Frédéric Pouliot, Éric Lévesque, Chantal Guillemette. Glucuronidation of Abiraterone and Its Pharmacologically Active Metabolites by UGT1A4, Influence of Polymorphic Variants and Their Potential as Inhibitors of Steroid Glucuronidation.
Drug metabolism and disposition: the biological fate of chemicals.
2020 02; 48(2):75-84. doi:
10.1124/dmd.119.088229. [PMID: 31727674] - A H Zedan, P J S Osther, J Assenholt, J S Madsen, T F Hansen. Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer.
Scientific reports.
2020 01; 10(1):227. doi:
10.1038/s41598-019-57101-7. [PMID: 31937854] - Daniel P Petrylak, Nicholas J Vogelzang, Kamal Chatta, Mark T Fleming, David C Smith, Leonard J Appleman, Arif Hussain, Manuel Modiano, Parminder Singh, Scott T Tagawa, Ira Gore, Edward F McClay, Anthony E Mega, A Oliver Sartor, Bradley Somer, Raymond Wadlow, Neal D Shore, William C Olson, Nancy Stambler, Vincent A DiPippo, Robert J Israel. PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.
The Prostate.
2020 01; 80(1):99-108. doi:
10.1002/pros.23922. [PMID: 31742767] - Merel van Nuland, Julie M Janssen, Bart van Hoek, Hilde Rosing, Jos H Beijnen, André M Bergman. Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant.
Clinical genitourinary cancer.
2019 10; 17(5):e893-e896. doi:
10.1016/j.clgc.2019.05.026. [PMID: 31248829] - Atul Bhatnagar, Matthew J McKay, Morten Thaysen-Andersen, Malmaruha Arasaratnam, Megan Crumbaker, Howard Gurney, Mark P Molloy. Bioanalytical evaluation of dried plasma spots for monitoring of abiraterone and ∆(4)-abiraterone from cancer patients.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2019 Sep; 1126-1127(?):121741. doi:
10.1016/j.jchromb.2019.121741. [PMID: 31421381] - Klara Kvorning Ternov, Jens Sønksen, Mikkel Fode, Henriette Lindberg, Caroline Michaela Kistorp, Rasmus Bisbjerg, Ganesh Palapattu, Peter Busch Østergren. Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol.
BMJ open.
2019 09; 9(9):e030218. doi:
10.1136/bmjopen-2019-030218. [PMID: 31511288] - Cecilie Hurup Munkboel, Tobias Bangsgaard Rasmussen, Camilla Elgaard, Maja-Luna Kingo Olesen, Andreas Christopher Kretschmann, Bjarne Styrishave. The classic azole antifungal drugs are highly potent endocrine disruptors in vitro inhibiting steroidogenic CYP enzymes at concentrations lower than therapeutic Cmax.
Toxicology.
2019 09; 425(?):152247. doi:
10.1016/j.tox.2019.152247. [PMID: 31330226] - Toshihiko Doi, Yutaka Fujiwara, Nobuaki Matsubara, Junichi Tomomatsu, Satoru Iwasa, Akari Tanaka, Chihiro Endo-Tsukude, Shintaro Nakagawa, Shunji Takahashi. Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors.
Cancer chemotherapy and pharmacology.
2019 08; 84(2):393-404. doi:
10.1007/s00280-019-03882-7. [PMID: 31227862] - Cristian Lolli, Delia De Lisi, Vincenza Conteduca, Giorgia Gurioli, Emanuela Scarpi, Giuseppe Schepisi, Giorgia Ravaglia, Cecilia Menna, Alberto Farolfi, Amelia Altavilla, Salvatore Luca Burgio, Giuseppe Tonini, Daniele Santini, Ugo De Giorgi. Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide.
The Prostate.
2019 08; 79(11):1211-1220. doi:
10.1002/pros.23804. [PMID: 31251826] - Malmaruha Arasaratnam, Megan Crumbaker, Atul Bhatnagar, Matthew J McKay, Mark P Molloy, Howard Gurney. Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer.
Cancer chemotherapy and pharmacology.
2019 07; 84(1):139-146. doi:
10.1007/s00280-019-03862-x. [PMID: 31081533] - Kohei Hashimoto, Hidetoshi Tabata, Tetsuya Shindo, Toshiaki Tanaka, Jiro Hashimoto, Ryuta Inoue, Takashi Muranaka, Hiroshi Hotta, Masahiro Yanase, Yasuharu Kunishima, Atsushi Takahashi, Naoya Masumori. Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer.
Urologic oncology.
2019 07; 37(7):485-491. doi:
10.1016/j.urolonc.2019.04.026. [PMID: 31103335] - Sumanta K Pal, Dayson Moreira, Haejung Won, Seok Woon White, Pryanka Duttagupta, Marc Lucia, Jeremy Jones, JoAnn Hsu, Marcin Kortylewski. Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy.
International journal of molecular sciences.
2019 Apr; 20(8):. doi:
10.3390/ijms20081831. [PMID: 31013891] - Toshimitsu Tsugu, Yuji Nagatomo, Yuki Nakajima, Toshimi Kageyama, Yushi Akise, Jin Endo, Yuji Itabashi, Mitsushige Murata, Hideo Mitamura. Cancer therapeutics-related cardiac dysfunction in a patient treated with abiraterone for castration-resistant prostate cancer.
Journal of medical ultrasonics (2001).
2019 Apr; 46(2):239-243. doi:
10.1007/s10396-018-0897-7. [PMID: 30151629] - Guijiang Sun, Xuanrong Chen, Ue Gong, Yawei Chen, Guilai Li, Fang Wei, Aili Jiang, Yuanjie Niu, Zhiqun Shang. Androgen deprivation therapy with chemotherapy or abiraterone for patients with metastatic hormone-naive prostate cancer: a systematic review and meta-analysis.
Future oncology (London, England).
2019 Apr; 15(10):1167-1179. doi:
10.2217/fon-2018-0619. [PMID: 30741558] - Takayuki Sumiyoshi, Kei Mizuno, Toshinari Yamasaki, Yu Miyazaki, Yuki Makino, Kosuke Okasho, Xin Li, Noriaki Utsunomiya, Takayuki Goto, Takashi Kobayashi, Naoki Terada, Takahiro Inoue, Tomomi Kamba, Akihiro Fujimoto, Osamu Ogawa, Shusuke Akamatsu. Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer.
Scientific reports.
2019 03; 9(1):4030. doi:
10.1038/s41598-019-40719-y. [PMID: 30858508] - Stefanie L Groenland, Merel van Nuland, Remy B Verheijen, Jan H M Schellens, Jos H Beijnen, Alwin D R Huitema, Neeltje Steeghs. Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology.
Clinical pharmacokinetics.
2019 03; 58(3):299-308. doi:
10.1007/s40262-018-0683-0. [PMID: 29862467] - Vincenza Conteduca, Anuradha Jayaram, Nuria Romero-Laorden, Daniel Wetterskog, Samanta Salvi, Giorgia Gurioli, Emanuela Scarpi, Elena Castro, Mercedes Marin-Aguilera, Cristian Lolli, Giuseppe Schepisi, Antonio Maugeri, Anna Wingate, Alberto Farolfi, Valentina Casadio, Ana Medina, Javier Puente, Mª José Méndez Vidal, Rafael Morales-Barrera, Jose C Villa-Guzmán, Susana Hernando, Alejo Rodriguez-Vida, Aránzazu González-Del-Alba, Begoña Mellado, Enrique Gonzalez-Billalabeitia, David Olmos, Gerhardt Attard, Ugo De Giorgi. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
European urology.
2019 03; 75(3):368-373. doi:
10.1016/j.eururo.2018.09.049. [PMID: 30773204] - Mohammed Bouhajib, Zia Tayab. Evaluation of the Pharmacokinetics of Abiraterone Acetate and Abiraterone Following Single-Dose Administration of Abiraterone Acetate to Healthy Subjects.
Clinical drug investigation.
2019 Mar; 39(3):309-317. doi:
10.1007/s40261-019-00752-1. [PMID: 30671920] - Masaki Shiota, Eiji Kashiwagi, Tomohiko Murakami, Ario Takeuchi, Kenjiro Imada, Junichi Inokuchi, Katsunori Tatsugami, Masatoshi Eto. Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer.
Urologic oncology.
2019 03; 37(3):180.e19-180.e24. doi:
10.1016/j.urolonc.2018.10.020. [PMID: 30446464] - M van Nuland, N Venekamp, N de Vries, K A M de Jong, H Rosing, J H Beijnen. Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2019 Feb; 1106-1107(?):26-34. doi:
10.1016/j.jchromb.2019.01.001. [PMID: 30639947] - Patrick Caron, Véronique Turcotte, Eric Lévesque, Chantal Guillemette. An LC-MS/MS method for quantification of abiraterone, its active metabolites D(4)-abiraterone (D4A) and 5α-abiraterone, and their inactive glucuronide derivatives.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2019 Jan; 1104(?):249-255. doi:
10.1016/j.jchromb.2018.12.003. [PMID: 30537624] - Nuria Romero-Laorden, Rebeca Lozano, Anuradha Jayaram, Fernando López-Campos, Maria I Saez, Alvaro Montesa, Ana Gutierrez-Pecharoman, Rosa Villatoro, Bernardo Herrera, Raquel Correa, Adriana Rosero, María I Pacheco, Teresa Garcés, Ylenia Cendón, Ma Paz Nombela, Floortje Van de Poll, Gala Grau, Leticia Rivera, Pedro P López, Juan-Jesús Cruz, David Lorente, Gerhardt Attard, Elena Castro, David Olmos. Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study).
British journal of cancer.
2018 10; 119(9):1052-1059. doi:
10.1038/s41416-018-0123-9. [PMID: 30131546] - Jelena Belic, Ricarda Graf, Thomas Bauernhofer, Yauheniya Cherkas, Peter Ulz, Julie Waldispuehl-Geigl, Samantha Perakis, Michael Gormley, Jaymala Patel, Weimin Li, Jochen B Geigl, Denis Smirnov, Ellen Heitzer, Mitchell Gross, Michael R Speicher. Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.
International journal of cancer.
2018 09; 143(5):1236-1248. doi:
10.1002/ijc.31397. [PMID: 29574703] - Fred Saad. Improving outcome in patients with prostate and kidney cancer: heading in the right direction?.
Current opinion in supportive and palliative care.
2018 09; 12(3):323-324. doi:
10.1097/spc.0000000000000368. [PMID: 30074925] - Mohammad Alyamani, Hamid Emamekhoo, Sunho Park, Jennifer Taylor, Nima Almassi, Sunil Upadhyay, Allison Tyler, Michael P Berk, Bo Hu, Tae Hyun Hwang, William Douglas Figg, Cody J Peer, Caly Chien, Vadim S Koshkin, Prateek Mendiratta, Petros Grivas, Brian Rini, Jorge Garcia, Richard J Auchus, Nima Sharifi. HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer.
The Journal of clinical investigation.
2018 08; 128(8):3333-3340. doi:
10.1172/jci98319. [PMID: 29939161] - Michael Dineen, Elizabeth Hansen, Elizabeth Guancial, Lynn Sievert, Deepak Sahasrabudhe. Abiraterone-induced rhabdomyolysis resulting in acute kidney injury: A case report and review of the literature.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2018 Jun; 24(4):314-318. doi:
10.1177/1078155217701294. [PMID: 28355968] - Atul Bhatnagar, Matthew J McKay, Megan Crumbaker, Ketan Ahire, Peter Karuso, Howard Gurney, Mark P Molloy. Quantitation of the anticancer drug abiraterone and its metabolite Δ(4)-abiraterone in human plasma using high-resolution mass spectrometry.
Journal of pharmaceutical and biomedical analysis.
2018 May; 154(?):66-74. doi:
10.1016/j.jpba.2018.03.012. [PMID: 29533860] - Russell Z Szmulewitz, Cody J Peer, Abiola Ibraheem, Elia Martinez, Mark F Kozloff, Bradley Carthon, R Donald Harvey, Paul Fishkin, Wei Peng Yong, Edmund Chiong, Chadi Nabhan, Theodore Karrison, William D Figg, Walter M Stadler, Mark J Ratain. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2018 05; 36(14):1389-1395. doi:
10.1200/jco.2017.76.4381. [PMID: 29590007] - Anuradha Jayaram, Daniel Wetterskog, Gerhardt Attard. Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker Test.
Cancer discovery.
2018 04; 8(4):392-394. doi:
10.1158/2159-8290.cd-18-0124. [PMID: 29610288] - Matti Annala, Gillian Vandekerkhove, Daniel Khalaf, Sinja Taavitsainen, Kevin Beja, Evan W Warner, Katherine Sunderland, Christian Kollmannsberger, Bernhard J Eigl, Daygen Finch, Conrad D Oja, Joanna Vergidis, Muhammad Zulfiqar, Arun A Azad, Matti Nykter, Martin E Gleave, Alexander W Wyatt, Kim N Chi. Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.
Cancer discovery.
2018 04; 8(4):444-457. doi:
10.1158/2159-8290.cd-17-0937. [PMID: 29367197] - Daniel Hettel, Nima Sharifi. HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.
Nature reviews. Urology.
2018 Mar; 15(3):191-196. doi:
10.1038/nrurol.2017.201. [PMID: 29231195] - Valentina Murdica, Giulia Mancini, Nicoletta Loberto, Rosaria Bassi, Paola Giussani, Nadia Di Muzio, Chiara Deantoni, Alessandro Prinetti, Massimo Aureli, Sandro Sonnino. Abiraterone and Ionizing Radiation Alter the Sphingolipid Homeostasis in Prostate Cancer Cells.
Advances in experimental medicine and biology.
2018 ; 1112(?):293-307. doi:
10.1007/978-981-13-3065-0_20. [PMID: 30637705] - Terence W Friedlander, Julie N Graff, Kreshnik Zejnullahu, Archana Anantharaman, Li Zhang, Rosa Paz, Gayatri Premasekharan, Carly Russell, Yong Huang, Won Kim, Rahul R Aggarwal, Amy M Lin, Lawrence Fong, Joshi J Alumkal, Tomasz M Beer, Nima Sharifi, Mohammad Alyamani, Ryan Dittamore, Eric J Small, Pamela L Paris, Charles J Ryan. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer.
Clinical genitourinary cancer.
2017 12; 15(6):733-741.e1. doi:
10.1016/j.clgc.2017.05.026. [PMID: 28655452] - Merel van Nuland, Hilde Rosing, Jelle de Vries, Huib Ovaa, Jan H M Schellens, Jos H Beijnen. An LC-MS/MS method for quantification of the active abiraterone metabolite Δ(4)-abiraterone (D4A) in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2017 Nov; 1068-1069(?):119-124. doi:
10.1016/j.jchromb.2017.10.033. [PMID: 29059586] - V Conteduca, E Scarpi, P Caroli, S Salvi, C Lolli, S L Burgio, C Menna, G Schepisi, S Testoni, G Gurioli, G Paganelli, V Casadio, F Matteucci, U De Giorgi. Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer.
Scientific reports.
2017 Nov; 7(1):15541. doi:
10.1038/s41598-017-15928-y. [PMID: 29138500] - Antonio G Gomes de Mello Martins, Giuseppe Allegretta, Gerhard Unteregger, Jörg Haupenthal, Jens Eberhard, Michael Hoffmann, Jill A van der Zee, Kerstin Junker, Michael Stöckle, Rolf Müller, Rolf W Hartmann, Carsten-H Ohlmann. CYP17A1-independent production of the neurosteroid-derived 5α-pregnan-3β,6α-diol-20-one in androgen-responsive prostate cancer cell lines under serum starvation and inhibition by Abiraterone.
The Journal of steroid biochemistry and molecular biology.
2017 11; 174(?):183-191. doi:
10.1016/j.jsbmb.2017.09.006. [PMID: 28890368] - Guillemette E Benoist, Eric van der Meulen, Floor J E Lubberman, Winald R Gerritsen, Tineke J Smilde, Jack A Schalken, Jan H Beumer, David M Burger, Nielka P van Erp. Analytical challenges in quantifying abiraterone with LC-MS/MS in human plasma.
Biomedical chromatography : BMC.
2017 Nov; 31(11):. doi:
10.1002/bmc.3986. [PMID: 28370076] - Valentina Bertaglia, Marcello Tucci, Francesca Vignani, Consuelo Buttigliero, Emiliano Aroasio, Alfredo Berruti, Giorgio V Scagliotti, Massimo DI Maio. An exploratory analysis of the association between levels of hormones implied in steroid biosynthesis and activity of abiraterone in patients with metastatic castration-resistant prostate cancer.
Minerva urologica e nefrologica = The Italian journal of urology and nephrology.
2017 Aug; 69(4):349-358. doi:
10.23736/s0393-2249.16.02746-6. [PMID: 28008755] - V Conteduca, D Wetterskog, M T A Sharabiani, E Grande, M P Fernandez-Perez, A Jayaram, S Salvi, D Castellano, A Romanel, C Lolli, V Casadio, G Gurioli, D Amadori, A Font, S Vazquez-Estevez, A González Del Alba, B Mellado, O Fernandez-Calvo, M J Méndez-Vidal, M A Climent, I Duran, E Gallardo, A Rodriguez, C Santander, M I Sáez, J Puente, D Gasi Tandefelt, A Wingate, D Dearnaley, F Demichelis, U De Giorgi, E Gonzalez-Billalabeitia, G Attard. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.
Annals of oncology : official journal of the European Society for Medical Oncology.
2017 Jul; 28(7):1508-1516. doi:
10.1093/annonc/mdx155. [PMID: 28472366] - Merel van Nuland, M J X Hillebrand, H Rosing, J H M Schellens, J H Beijnen. Development and Validation of an LC-MS/MS Method for the Simultaneous Quantification of Abiraterone, Enzalutamide, and Their Major Metabolites in Human Plasma.
Therapeutic drug monitoring.
2017 06; 39(3):243-251. doi:
10.1097/ftd.0000000000000387. [PMID: 28490047] - Mingliang Wang, Yanjia Fang, Shoulai Gu, Fangfang Chen, Zhengjiang Zhu, Xun Sun, Jidong Zhu. Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors.
European journal of medicinal chemistry.
2017 May; 132(?):157-172. doi:
10.1016/j.ejmech.2017.03.037. [PMID: 28350999] - Kyu-Pyo Kim, Robert A Parise, Julianne L Holleran, Lionel D Lewis, Leonard Appleman, Nielka van Erp, Michael J Morris, Jan H Beumer. Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS.
Journal of pharmaceutical and biomedical analysis.
2017 May; 138(?):197-205. doi:
10.1016/j.jpba.2017.02.018. [PMID: 28219796] - Marzia Del Re, Elisa Biasco, Stefania Crucitta, Lisa Derosa, Eleonora Rofi, Cinzia Orlandini, Mario Miccoli, Luca Galli, Alfredo Falcone, Guido W Jenster, Ron H van Schaik, Romano Danesi. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.
European urology.
2017 04; 71(4):680-687. doi:
10.1016/j.eururo.2016.08.012. [PMID: 27733296] - Rana R McKay, Lillian Werner, Elahe A Mostaghel, Rosina Lis, Olga Voznesensky, Zhenwei Zhang, Brett T Marck, Alvin M Matsumoto, Liran Domachevsky, Katherine A Zukotynski, Manoj Bhasin, Glenn J Bubley, Bruce Montgomery, Philip W Kantoff, Steven P Balk, Mary-Ellen Taplin. A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2017 Feb; 23(4):935-945. doi:
10.1158/1078-0432.ccr-16-0987. [PMID: 27683182] - E Carton, G Noe, O Huillard, L Golmard, J Giroux, A Cessot, N E B Saidu, M Peyromaure, M Zerbib, C Narjoz, J Guibourdenche, A Thomas, M Vidal, F Goldwasser, B Blanchet, J Alexandre. Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients.
European journal of cancer (Oxford, England : 1990).
2017 02; 72(?):54-61. doi:
10.1016/j.ejca.2016.11.027. [PMID: 28027516] - Matthias M Heck, Markus A Thaler, Sebastian C Schmid, Anna-Katharina Seitz, Robert Tauber, Hubert Kübler, Tobias Maurer, Mark Thalgott, Georgios Hatzichristodoulou, Michael Höppner, Roman Nawroth, Peter B Luppa, Jürgen E Gschwend, Margitta Retz. Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy.
BJU international.
2017 Jan; 119(1):30-37. doi:
10.1111/bju.13493. [PMID: 27037533] - Orazio Caffo, Nima Sharifi. Could Steroidal Abiraterone Metabolites Possibly Explain Abiraterone Withdrawal Syndrome?.
European urology.
2016 11; 70(5):898-899. doi:
10.1016/j.eururo.2016.06.013. [PMID: 27339836] - Zhenfei Li, Mohammad Alyamani, Jianneng Li, Kevin Rogacki, Mohamed Abazeed, Sunil K Upadhyay, Steven P Balk, Mary-Ellen Taplin, Richard J Auchus, Nima Sharifi. Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.
Nature.
2016 05; 533(7604):547-51. doi:
10.1038/nature17954. [PMID: 27225130] - Alessandro Romanel, Delila Gasi Tandefelt, Vincenza Conteduca, Anuradha Jayaram, Nicola Casiraghi, Daniel Wetterskog, Samanta Salvi, Dino Amadori, Zafeiris Zafeiriou, Pasquale Rescigno, Diletta Bianchini, Giorgia Gurioli, Valentina Casadio, Suzanne Carreira, Jane Goodall, Anna Wingate, Roberta Ferraldeschi, Nina Tunariu, Penny Flohr, Ugo De Giorgi, Johann S de Bono, Francesca Demichelis, Gerhardt Attard. Plasma AR and abiraterone-resistant prostate cancer.
Science translational medicine.
2015 Nov; 7(312):312re10. doi:
10.1126/scitranslmed.aac9511. [PMID: 26537258] - Javier A Neyra, Natalia A Rocha, Rhea Bhargava, Omkar U Vaidya, Allen R Hendricks, Aylin R Rodan. Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone: a case report.
BMC nephrology.
2015 Jul; 16(?):118. doi:
10.1186/s12882-015-0113-6. [PMID: 26220655] - Zhenfei Li, Andrew C Bishop, Mohammad Alyamani, Jorge A Garcia, Robert Dreicer, Dustin Bunch, Jiayan Liu, Sunil K Upadhyay, Richard J Auchus, Nima Sharifi. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.
Nature.
2015 Jul; 523(7560):347-51. doi:
10.1038/nature14406. [PMID: 26030522] - Michele Iuliani, Francesco Pantano, Consuelo Buttigliero, Marco Fioramonti, Valentina Bertaglia, Bruno Vincenzi, Alice Zoccoli, Giulia Ribelli, Marcello Tucci, Francesca Vignani, Alfredo Berruti, Giorgio Vittorio Scagliotti, Giuseppe Tonini, Daniele Santini. Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment.
Oncotarget.
2015 May; 6(14):12520-8. doi:
10.18632/oncotarget.3724. [PMID: 25904051] - Arun A Azad, Stanislav V Volik, Alexander W Wyatt, Anne Haegert, Stephane Le Bihan, Robert H Bell, Shawn A Anderson, Brian McConeghy, Robert Shukin, Jenny Bazov, Jack Youngren, Pamela Paris, George Thomas, Eric J Small, Yuzhuo Wang, Martin E Gleave, Colin C Collins, Kim N Chi. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2015 May; 21(10):2315-24. doi:
10.1158/1078-0432.ccr-14-2666. [PMID: 25712683] - S Salvi, V Casadio, V Conteduca, S L Burgio, C Menna, E Bianchi, L Rossi, E Carretta, C Masini, D Amadori, D Calistri, G Attard, U De Giorgi. Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.
British journal of cancer.
2015 May; 112(10):1717-24. doi:
10.1038/bjc.2015.128. [PMID: 25897673] - Tiphaine Belleville, Gaëlle Noé, Olivier Huillard, Audrey Thomas-Schoemann, Michel Vidal, François Goldwasser, Jerome Alexandre, Benoit Blanchet. A HPLC-fluorescence method for the quantification of abiraterone in plasma from patients with metastatic castration-resistant prostate cancer.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2015 May; 989(?):86-90. doi:
10.1016/j.jchromb.2015.03.001. [PMID: 25813901] - Salvatore L Burgio, Vincenza Conteduca, Britt Rudnas, Francesco Carrozza, Enrico Campadelli, Emanuela Bianchi, Paolo Fabbri, Marco Montanari, Elisa Carretta, Cecilia Menna, Ugo De Giorgi. PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer.
Clinical genitourinary cancer.
2015 Feb; 13(1):39-43. doi:
10.1016/j.clgc.2014.06.010. [PMID: 24999168] - Ellen L Berg, Mark A Polokoff, Alison O'Mahony, Dat Nguyen, Xitong Li. Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems--a chemical biology approach for thrombosis-related side effects.
International journal of molecular sciences.
2015 Jan; 16(1):1008-29. doi:
10.3390/ijms16011008. [PMID: 25569083] - Fernand Labrie. Combined blockade of testicular and locally made androgens in prostate cancer: a highly significant medical progress based upon intracrinology.
The Journal of steroid biochemistry and molecular biology.
2015 Jan; 145(?):144-56. doi:
10.1016/j.jsbmb.2014.05.012. [PMID: 24925260] - Kim Stuyckens, Fred Saad, Xu Steven Xu, Charles J Ryan, Matthew R Smith, Thomas W Griffin, Margaret K Yu, An Vermeulen, Partha Nandy, Italo Poggesi. Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer.
Clinical pharmacokinetics.
2014 Dec; 53(12):1149-60. doi:
10.1007/s40262-014-0178-6. [PMID: 25204404] - Edoardo Francini, Roberto Petrioli, Anna Ida Fiaschi, Letizia Laera, Giandomenico Roviello. Effects of abiraterone acetate on chronic kidney disease in 2 patients with metastatic castration-resistant prostate cancer.
Medicine.
2014 Dec; 93(27):e163. doi:
10.1097/md.0000000000000163. [PMID: 25501058] - Takefumi Satoh, Hiroji Uemura, Kazunari Tanabe, Tsutomu Nishiyama, Akito Terai, Akira Yokomizo, Tatsuya Nakatani, Keiichiro Imanaka, Seiichiro Ozono, Hideyuki Akaza. A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy.
Japanese journal of clinical oncology.
2014 Dec; 44(12):1206-15. doi:
10.1093/jjco/hyu148. [PMID: 25425730] - Nobuaki Matsubara, Hiroji Uemura, Iwao Fukui, Masashi Niwakawa, Akito Yamaguchi, Koho Iizuka, Hideyuki Akaza. Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer.
Cancer science.
2014 Oct; 105(10):1313-20. doi:
10.1111/cas.12496. [PMID: 25117615] - Eva Gupta, Troy Guthrie, Winston Tan. Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).
BMC urology.
2014 Jul; 14(?):55. doi:
10.1186/1471-2490-14-55. [PMID: 25062956] - C J Ryan, W Peng, T Kheoh, E Welkowsky, C M Haqq, D W Chandler, H I Scher, A Molina. Androgen dynamics and serum PSA in patients treated with abiraterone acetate.
Prostate cancer and prostatic diseases.
2014 Jun; 17(2):192-8. doi:
10.1038/pcan.2014.8. [PMID: 24637537]